Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

Global Real-World Evidence (RWE) Solutions Market Report 2021: Market is Expected to Grow at a CAGR of 11.8% to 2028 to Reach $4.4 Billion

Published

on

Dublin, Jan. 13, 2022 (GLOBE NEWSWIRE) — The “Real-World Evidence (RWE) Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) – Global Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering.

The RWE solutions market is expected to grow at a CAGR of 11.8% from 2021 to 2028 to reach $4.4 billion by 2028

Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are the key factors driving the growth of the global RWE solutions market. Further, significant growth opportunities for existing market players and new entrants are provided by emerging markets, rising focus on end-to-end RWE services, and the rising adoption of wearable devices and AI in RWE.

Based on component, the datasets segment is expected to command the largest share of the global RWE solutions market due to factors such as the rising dependence of outcome-based studies on real-world data, increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment, the growing amount of medical data generated in hospitals, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Based on application, the drug development & approvals segment is expected to witness the fastest growth rate during the forecast period. The increasing investments by pharma and biopharma companies in R&D, increasing demand for real-world data and real-world evidence for accelerating drug discovery and development, and the growing inclination of regulatory bodies towards the use of real-world evidence (RWE) are the factors contributing to the growth of this segment.

Based on end user, the pharmaceutical, biotechnology, & medical device companies segment is expected to witness the fastest growth rate during the forecast period. The increasing importance of RWE studies in drug development &approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings are the factors contributing to the growth of this segment.

An in-depth analysis of the geographical scenario of the RWE solutions market provides detailed qualitative and quantitative insights about the five major geographies (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is expected to command the largest share of the global RWE solutions market in 2021, followed by Asia-Pacific and Europe.

Market Insights

Drivers

  • Growing Burden of Chronic Diseases
  • Rising Focus Towards Personalized Healthcare
  • Delays in Drug Development and the Subsequent Increase in Development Costs
  • Shift Towards Value-Based Care
  • Rapidly Growing Big Data in Healthcare

Restraints

  • Reluctance to Rely on Real-World Studies

Opportunities

  • Emerging Economies
  • Rising Focus on End-To-End RWE Services
  • Rising Adoption of Wearable Devices and Artificial Intelligence in RWE

Challenges

  • Lack of Standardized Methodologies to Develop RWE
  • Impact Assessment of COVID-19

Key Market Trends

  • Growing Adoption of RWE in Drug Development and Commercialization
  • Rising Number of Consolidations
  • Improved Patient Outcomes and value Creation from real world Evidence

Pricing Models (Emr/Genomic/Integrated Datasets)

  • Pay Per Patient Record (Volume-Based Pricing)
  • Pay Per Usage (Value-Based Pricing)
  • Annual Subscription

The key companies operating in the global RWE solutions market are

  • IQVIA Holdings Inc.
  • ICON plc
  • PPD Inc.
  • SYNEOS HEALTH Inc.
  • CLARIVATE PLC
  • Medpace Holdings Inc.
  • Symphony Innovation LLC
  • Clinigen Group plc
  • Cognizant Technology Solutions Corporation
  • IBM Corporation
  • Oracle Corporation
  • PAREXEL International Corporation
  • PerkinElmer Inc.
  • SAS Institute Inc.
  • UnitedHealth Group Incorporated
  • Flatiron Health

Scope of the Report

Global RWE Solutions Market, by Component

  • Datasets
  • Disparate Datasets
  • EMR/EHR/Clinical Data
  • Claims & Billing Data
  • Pharmacy Data
  • Product/Disease Registries Data
  • Other Disparate Datasets
  • Integrated Datasets
  • Consulting & Analytics

(Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

Global RWE Solutions Market, by Application

  • Market Access & Reimbursement/Coverage Decisions
  • Drug Development & Approvals
  • Oncology
  • Neurology
  • Immunology
  • Cardiovascular Diseases
  • Other Therapeutic Areas
  • Post Market Surveillance
  • Medical Device Development & Approvals
  • Other Applications

(Note: Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases, Other Applications include regulatory and clinical decision-making)

Global RWE Solutions Market, by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users

(Note: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

Global RWE Solutions Market, by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Singapore
  • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

For more information about this report visit https://www.researchandmarkets.com/r/8dcjxf


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

TRON Forum collaborates with four major microcontroller manufacturers to hold TRON Programming Contest Using World-Standard Real-Time OS with 5 million JP YEN cash prize

Published

on

tron-forum-collaborates-with-four-major-microcontroller-manufacturers-to-hold-tron-programming-contest-using-world-standard-real-time-os-with-5-million-jp-yen-cash-prize

TOKYO, March 29, 2024 /PRNewswire/ — TRON Forum (Chair: Ken Sakamura, Professor Emeritus of the University of Tokyo) is pleased to announce that four microcontroller manufacturers, Infineon Technologies Japan K.K. (President & CEO: Ikuya Kawasaki), STMicroelectronics K.K. (Country Manager for Japan: Koichiro Takakuwa), NXP Japan K.K. (President & CEO: Masayuki Wajima), and Renesas Electronics Corporation (President & CEO: Hidetoshi Shibata) have collaborated with the Forum to hold TRON Programming Contest from Monday, December 11, 2023 jointly. The initial registration is being accepted now.

This contest is for engineers and students in Japan and overseas to compete in various  fields such as microcontroller applications, middleware, development environments, and tools using a member of TRON real-time OS (RTOS) family, “μT-Kernel 3.0” (*), which is a global standard of small-scale embedded computer systems.
(*) μT-Kernel 3.0 is an RTOS that fully complies with the real-time OS standard “IEEE 2050-2018” (IEEE Standard for a Real-Time Operating System (RTOS) for Small-Scale Embedded Systems) and runs on microcontrollers from various manufacturers.
Using the latest microcomputer boards provided by the manufacturers, contestants will compete in technologies that bring out the characteristics of RTOSs such as real-time performance, power saving, and small memory footprint, as well as development environments and tools that utilize new technologies.
The details of the contest with the total amount of cash prize, five million Japanese yen are at the following URL: https://www.tron.org/programming_contest/
About TRON Forum
TRON Forum was established in 2002 to promote TRON Project. We have been actively conducting activities centered on the T-Engine project, which prepares the development environment for embedded systems, and the operation of Ubiquitous ID Centers such as ucode.
In May 2015, Chair Sakamura received the ITU 150th Anniversary Award together with Bill Gates and others for his advocacy of open architecture TRON, which is the origin of ubiquitous networking and the IoT.
One member of the TRON RTOS family has been adopted as an international standard for real-time operating systems (RTOS) for small-scale embedded systems as 2050-2018 by Institute of Electrical and Electronics Engineers (IEEE), the world’s largest association of its kind and an international standardization organization. In 2023, the project leader, Chair Sakamura, received the IEEE Masaru Ibuka Consumer Technology Award from the IEEE in honor of the late Mr. Ibuka. In addition, the TRON RTOS family received the IEEE Milestone recognition in 2023.
URL: https://www.tron.org 
 
 

View original content:https://www.prnewswire.co.uk/news-releases/tron-forum-collaborates-with-four-major-microcontroller-manufacturers-to-hold-tron-programming-contest-using-world-standard-real-time-os-with-5-million-jp-yen-cash-prize-302103284.html

Continue Reading

Artificial Intelligence

XtalPi Unveils XtalGazer: A Comprehensive AI-Driven Polymorph Selection Platform

Published

on

xtalpi-unveils-xtalgazer:-a-comprehensive-ai-driven-polymorph-selection-platform

CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ — XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer. This advanced platform aims to significantly improve the polymorph selection process for the pharmaceutical industry by integrating AI- and automation-powered experimental and computational approaches.

XtalGazer provides a total solution for delivering high-quality polymorph screening and selection methods to expedite drug development and mitigate risks. It represents a paradigm shift in solid-state research, moving from the traditional trial-and-error approach to a data-driven, design-led methodology. The platform provides an expansive suite of foundational tools to accelerate polymorph discovery, characterization, and selection process, empowering pharmaceutical companies to conduct thorough research with less active pharmaceutical ingredient (API) in shorter development cycles.
A key component of XtalGazer is XtalCSP, a crystal structure prediction platform to perform global searches of crystal structures for target molecules and the other optional components in the corresponding searching space, offering a deep insight into possible stable forms. Furthermore, crystallization strategy recommendations will provide AI-backed experimental design to help avoid human bias. XtalGazer also utilizes MicroED to rapidly elucidate crystal structures from powder samples, reducing the need for growing single crystals.
XtalPi’s launch of XtalGazer marks another significant step in the company’s ongoing exploration of solid-state research. From crystal structure prediction platforms being one of the first products to launch at XtalPi, to today’s comprehensive polymorph selection platform, XtalPi will keep fulfilling its promise to solving challenging problems in this space. XtalPi will continue to deliver faster, more accurate, and more comprehensive approaches to building an ecosystem for the R&D process in solid-state, pre-formulation and crystallization.
For more information about XtalPi, please visit www.xtalpi.com.
About XtalPi:
XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.
Media Contact: Vivienne [email protected]
Logo – https://mma.prnewswire.com/media/632519/XtalPi_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/xtalpi-unveils-xtalgazer-a-comprehensive-ai-driven-polymorph-selection-platform-302102794.html

Continue Reading

Artificial Intelligence

ICIS and Base Oil News Announce Partnership to Enhance Market Insights

Published

on

icis-and-base-oil-news-announce-partnership-to-enhance-market-insights

LONDON, March 28, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News, a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market. This collaboration marks a significant milestone in the dissemination and exchange of critical market data and insights.

With more than two decades of journalism experience at Bloomberg, Reuters, and Argus Media, Iain Pocock brings unparalleled expertise to this partnership. His deep understanding of illiquid energy markets makes him a credible and influential figure in the industry. Since November 2023, Iain has been working closely with ICIS to share and exchange valuable data and insights, enhancing the services both platforms offer to the base oils and lubricants market.
Through the collaboration, Iain integrates ICIS’ extensive content and data resources in Base Oil News market coverage. In return, he contributes market insights to ICIS News, including expert and exclusive analysis of supply and demand dynamics, price margins, and other critical market drivers. This exchange ensures that subscribers of both ICIS and Base Oil News have access to the most comprehensive, timely, and accurate market information, empowering them to make informed decisions.
“It’s a very exciting partnership – where we leverage each other’s strengths and provide actionable insights to our customers,” said Iain Pocock, Founder of Base Oil News. “The market is the winner.”
“As ICIS is already the world’s most trusted pricing benchmark for base oils, this collaboration with Iain Pocock and Base Oil News provides an even stronger and deeper service to our customers,” said Stephen Burns, Editorial Director at ICIS. “Iain’s expertise and extensive industry connections are invaluable, and we have established a fruitful partnership that benefits the market at large.”
For the latest insights from Iain Pocock on ICIS News, visit ICIS News.  
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, fertilizer and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of £64bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64bn | €75bn | $81bn.
Logo: https://mma.prnewswire.com/media/619935/4277787/ICIS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/icis-and-base-oil-news-announce-partnership-to-enhance-market-insights-302102782.html

Continue Reading
Advertisement

Latest News

Trending